- LIPIcontrol 2 what has changed after 3 years2020 | First Faculty of Medicine
- PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology2022 | First Faculty of Medicine
- Fixed-dose combination of rosuvastatin and ezetimibe2020 | First Faculty of Medicine
- New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO)2022 | Faculty of Medicine in Pilsen
- Fixed combination of atorvastatin and ezetimibe in the dyslipidemia treatment2020 | Faculty of Medicine in Pilsen
- The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis2021 | Faculty of Pharmacy in Hradec Králové
- The use of inactivation of the ANGPTL3 molecule in the treatment of dyslipidemia2022 | Faculty of Medicine in Hradec Králové
- Lipid-lowering in diabetes: An update2023 | First Faculty of Medicine
- Dyslipidemia - the known unknown2023 | First Faculty of Medicine
- Notes on the new "Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk"2019 | First Faculty of Medicine
- Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)2023 | First Faculty of Medicine
- Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)2021 | First Faculty of Medicine
- Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit2021 | First Faculty of Medicine
- Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics2022 | First Faculty of Medicine
- Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI2023 | First Faculty of Medicine
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publication without faculty affiliation
- Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?2022 | First Faculty of Medicine